Cited by 521Lipoproteins and Cardiovascular HealthGenetic Associations and EpidemiologyAtherosclerosis and Cardiovascular Diseases

The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.

Lipoprotein(a): resurrected by genetics

Open access

Kronenberg, F., Utermann, G.·2013·Journal of Internal Medicine

DOI 10.1111/j.1365-2796.2012.02592.x

Open this paper in CoChat — free account Open PDF

Abstract

Plasma lipoprotein(a) [L p(a)] is a quantitative genetic trait with a very broad and skewed distribution, which is largely controlled by genetic variants at the LPA locus on chromosome 6q27. Based on genetic evidence provided by studies conducted over the last two decades, L p(a) is currently considered to be the strongest genetic risk factor for coronary heart disease (CHD). The copy number variation of kringle IV in the LPA gene has been strongly associated with both L p(a) levels in plasma and risk of CHD, thereby fulfilling the main criterion for causality in a M endelian randomization approach. Alleles with a low kringle IV copy number that together have a population frequency of 25–35% are associated with a doubling of the relative risk for outcomes, which is exceptional in the field of complex genetic phenotypes. The recently identified binding of oxidized phospholipids to L p(a) is considered as one of the possible mechanisms that may explain the pathogenicity of L p(a). Drugs that have been shown to lower L p(a) have pleiotropic effects on other CHD risk factors, and an improvement of cardiovascular endpoints is up to now lacking. However, it has been established in a proof of principle study that lowering of very high L p(a) by apheresis in high‐risk patients with already maximally reduced low‐density lipoprotein cholesterol levels can dramatically reduce major coronary events.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2012.02592.x

Cites

204 of 204 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citation
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383

Flagged first, then by citations

Show all 203 references

Research works printed but not linked: 2

Utermann G, 2000, The Metabolic & Molecular Bases of Inherited Disease, 2753
10.1210/jc.81.7.2633 · DOI

Sorted by citations

Items 101–200 of 521

PCSK9 inhibitors and cardiovascular disease
Chapman, M. J., Stock, J. K., & Ginsberg, H. N. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000239 · Cited by 66
Recent advances in demystifying the metabolism of lipoprotein(a)
Chemello, K., Chan, D. C., Lambert, G. C., & Watts, G. F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.002 · Cited by 65
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
Volgman, A. S., Koschinsky, M. L., Mehta, A., & Rosenson, R. S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033654 · Cited by 68
Lipoprotein(a)
Tsimikas, S. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000237 · Cited by 64
Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients
Croyal, M., Ouguerram, K., Passard, M., Ferchaud‐Roucher, V., Chétiveaux, M., Billon‐Crossouard, S., de Gouville, A., Lambert, G. C., Krempf, M., & Nobécourt, E. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305835 · Cited by 62
Causal and Synthetic Associations of Variants in the SERPINA Gene Cluster with Alpha1-antitrypsin Serum Levels
Thun, G. A., Imboden, M., Ferrarotti, I., Kumar, A., Obeidat, M., Zorzetto, M., Haun, M., Curjuric, I., Alves, A. C., Jackson, V. E., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003585 · Cited by 62
Self-citation
Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis
Sahebkar, A., Simental‐Mendía, L. E., Stefanutti, C., & Pirro, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.030 · Cited by 61
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 60
Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: The Plaque at RISK (PARISK) study
van Dam-Nolen, D. H. K., van Dijk, A. C., Crombag, G. A. J. C., Lucci, C., Kooi, M. E., Hendrikse, J., Nederkoorn, P. J., Daemen, M. J. A. P., van der Steen, A. F. W., Koudstaal, P. J., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.004 · Cited by 60
Self-citation
Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke
Lange, K. S., Nave, A. H., Liman, T., Grittner, U., Endres, M., & Ebinger, M. (2016) · Stroke · doi:10.1161/strokeaha.116.014436 · Cited by 60
Lipoprotein(a) – An independent causal risk factor for cardiovascular disease and current therapeutic options
Kassner, U., Schlabs, T., Rosada, A., & Steinhagen‐Thiessen, E. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.039 · Cited by 59
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
Rider, D. A., Eisermann, M., Löffler, K., Aleku, M., Swerdlow, D. I., Dames, S., Hauptmann, J., Morrison, E., Lindholm, M., Schubert, S., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.029 · Cited by 59
Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model
Bissig-Choisat, B., Wang, L., Legras, X. D., Saha, P., Chen, L. L., Bell, P. L., Pankowicz, F. P., Hill, M. C., Barzi, M., Leyton, C. K., et al. (2015) · Nature Communications · doi:10.1038/ncomms8339 · Cited by 58
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 59
What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.004 · Cited by 59
Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions
Ellis, K. L., Pang, J., Chan, D. C., Hooper, A. J., Bell, D. A., Burnett, J. R., & Watts, G. F. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.011 · Cited by 57
Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype
Yahya, R., Berk, K. A., Verhoeven, A. J. M., Bos, S., van der Zee, L., Touw, J., Erhart, G., Kronenberg, F., Timman, R., Sijbrands, E. J. G., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.001 · Cited by 56
Self-citation
A comprehensive map of single-base polymorphisms in the hypervariable LPA kringle IV type 2 copy number variation region
Coassin, S., Schönherr, S., Weißensteiner, H., Erhart, G., Forer, L., Losso, J. L., Lamina, C., Haun, M., Utermann, G., Paulweber, B., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m090381 · Cited by 55
Self-citation
The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study
Ioannidou, A., Watts, E. L., Perez‐Cornago, A., Platz, E. A., Mills, I. G., Key, T. J., Travis, R. C., Tsilidis, K. K., & Zuber, V. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003859 · Cited by 52
Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns
Erhart, G., Lamina, C., Lehtimäki, T. J., Marques-Vidal, P. M., Kähönen, M. A. P., Vollenweider, P., Raitakari, O. T., Waeber, G., Thorand, B., Strauch, K., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310865 · Cited by 54
Self-citation
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region
Kronenberg, F. (2019) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-019-00093-5 · Cited by 55
Self-citation
Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification
Perrot, N., Thériault, S., Christian Dina, C., Chen, H. Y., Boekholdt, S. M., Rigade, S., Després, A.-A., Poulin, A., Capoulade, R., Tourneau, T. L., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1581 · Cited by 56
Lipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martı́n, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 60
Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Meroni, M., Longo, M., Lombardi, R., Paolini, E., Macchi, C., Corsini, A., Sirtori, C. R., Fracanzani, A. L., Ruscica, M., & Dongiovanni, P. (2022) · Hepatology Communications · doi:10.1002/hep4.1830 · Cited by 47
Oxidized phospholipids and lipoprotein‐associated phospholipase A2 ( Lp‐PLA2 ) in atherosclerotic cardiovascular disease: An update
Pantazi, D., Tellis, C. C., & Tselepis, A. D. (2022) · BioFactors · doi:10.1002/biof.1890 · Cited by 53
Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels
Lu, W., Cheng, Y., Chen, K. Y., Wang, H., Gerhard, G. S., Still, C. D., Chu, X., Yang, R., Parihar, A., O’Connell, J. R., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu731 · Cited by 54
Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100 578 Individuals from the General Population
Langsted, A., Varbo, A., Kamstrup, P. R., & Nordestgaard, B. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1096 · Cited by 53
Lipoprotein(a)
Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 54
Self-citation
Lipoprotein(a): from Causality to Treatment
Kronenberg, F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01187-6 · Cited by 55
Self-citation
Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role
Alexandros, D. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160009 · Cited by 52
Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
Romagnuolo, R., Scipione, C. A., Marcovina, S. M., Gemin, M., Seidah, N. G., Boffa, M. B., & Koschinsky, M. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180869 · Cited by 52
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
Croyal, M., Tran, T.-T.-T., Blanchard, R.-H., Bail, J.-C. L., Villard, E. F., Poirier, B., Aguesse, A., Billon‐Crossouard, S., Ramin‐Mangata, S., Blanchard, V., et al. (2018) · Clinical Science · doi:10.1042/cs20180040 · Cited by 54
Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal
Boffa, M. B., Stranges, S., Klar, N. S., Moriarty, P. M., Watts, G. F., & Koschinsky, M. L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.08.012 · Cited by 54
Antisense Oligonucleotides Targeting Lipoprotein(a)
Langsted, A., & Nordestgaard, B. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0792-8 · Cited by 50
Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study
Strandkjær, N., Hansen, M. K., Nielsen, S. T., Frikke‐Schmidt, R., Tybjærg‐Hansen, A., Nordestgaard, B. G., Tabor, A., Bundgaard, H., Iversen, K. K., & Kamstrup, P. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab734 · Cited by 51
Sequence Variation within the KIV-2 Copy Number Polymorphism of the Human LPA Gene in African, Asian, and European Populations
Noureen, A., Fresser, F., Utermann, G., & Schmidt, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121582 · Cited by 51
Self-citation
Innate Immune Memory in Monocytes and Macrophages: The Potential Therapeutic Strategies for Atherosclerosis
Guo, Z., Wang, L., Liu, H., & Xie, Y. (2022) · Cells · doi:10.3390/cells11244072 · Cited by 53
Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 Repeats
Tolbus, A., Mortensen, M. B., Nielsen, S. F., Kamstrup, P. R., Bojesen, S. E., & Nordestgaard, B. G. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.277103 · Cited by 50
Dietary natural products as emerging lipoprotein(a)‐lowering agents
Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 46
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45
Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?
Gómez, M. C. G. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.304 · Cited by 50
Heritability of Biomarkers of Oxidized Lipoproteins
Rao, F., Schork, A. J., Maihofer, A. X., Nievergelt, C. M., Marcovina, S. M., Miller, E. R., Witztum, J. L., O’Connor, D. T., & Tsimikas, S. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305306 · Cited by 45
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease
Doherty, S., Hernandez, S., Rikhi, R. R., Mirzai, S., Reyes, C. D. L., McIntosh, S. W., Block, R., & Shapiro, M. D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00760-1 · Cited by 50
Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study
Verbeek, R., Boekholdt, S. M., Stoekenbroek, R. M., Hovingh, G. K., Witztum, J. L., Wareham, N. J., Sandhu, M. S., Khaw, K., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066258 · Cited by 44
Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
Hopewell, J. C., Seedorf, U., Farrall, M., Parish, S., Kyriakou, T., Goel, A., Hamsten, A., Collins, R., Watkins, H. C., & Clarke, R. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12187 · Cited by 43
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Sosnowska, B., Stępińska, J., Mitkowski, P. P., Bielecka-Dabrowa, A. M., Bobrowska, B., Budzianowski, J., Burchardt, P., Chlebus, K., Dobrowolski, P., Gąsior, M., et al. (2024) · Archives of Medical Science · doi:10.5114/aoms/183522 · Cited by 50
High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study
Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.276931 · Cited by 42
New Therapeutic Targets for Calcific Aortic Valve Stenosis
Hung, M., Witztum, J. L., & Tsimikas, S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.1639 · Cited by 42
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 48
Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes
Berk, K. A., Yahya, R., Verhoeven, A. J. M., Touw, J., Leijten, F. P. J., van Rossum, E. F. C., Wester, V. L., Lips, M. A., Pijl, H., Timman, R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4246-y · Cited by 41
Self-citation
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 42
Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort
Brandt, E. J., Mani, A., Spatz, E. S., Desai, N. R., & Nasir, K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.06.010 · Cited by 41
Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
Virani, S. S., Koschinsky, M. L., Maher, L. V., Mehta, A., Orringer, C. E., Santos, R. D., Shapiro, M. D., & Saseen, J. J. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.01.002 · Cited by 42
South Asian Cardiovascular Disease & Cancer Risk: Genetics & Pathophysiology
Palaniappan, L. P., Garg, A., Enas, E. A., Lewis, H., Bari, S., Gulati, M., Flores, C., Mathur, A. K., Molina, C. R., Narula, J., et al. (2018) · Journal of Community Health · doi:10.1007/s10900-018-0527-8 · Cited by 45
Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals
Maio, S. D., Grüneis, R., Streiter, G., Lamina, C., Maglione, M., Schönherr, S., Öfner, D., Thorand, B., Peters, A., Eckardt, K., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00771-0 · Cited by 40
Self-citation
Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia
Bos, S., Duvekot, M. H. C., Blommesteijn-Touw, A. C., Verhoeven, A. J. M., Mulder, M. T., Watts, G. F., Sijbrands, E. J. G., & van Lennep, J. E. R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.024 · Cited by 39
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study
Kollerits, B., Drechsler, C., Krane, V., Lamina, C., März, W., Dieplinger, H., Ritz, E., Wanner, C., & Kronenberg, F. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv428 · Cited by 41
Self-citation
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 38
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
Wu, M., Xu, K., Guo, Y., Yu, J., Wu, Y., & Lin, L. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06906-9 · Cited by 38
Latest developments in the treatment of lipoprotein (a)
Bos, S., Yayha, R., & van Lennep, J. E. R. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000126 · Cited by 37
Lipoprotein(a) and risk of sudden cardiac death in middle-aged Finnish men: A new prospective cohort study
Kunutsor, S. K., Khan, H., Nyyssönen, K., & Laukkanen, J. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.069 · Cited by 37
Genome-Wide Association Study and Identification of a Protective Missense Variant on Lipoprotein(a) Concentration: Protective Missense Variant on Lipoprotein(a) Concentration—Brief Report
Said, M. A., Yeung, M. W., van de Vegte, Y. J., Benjamins, J. W., Dullaart, R. P. F., Ruotsalainen, S., Ripatti, S., Natarajan, P., Juarez-Orozco, L. E., Verweij, N., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315300 · Cited by 39
Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
Maio, S. D., Lamina, C., Coassin, S., Forer, L., Würzner, R., Schönherr, S., & Kronenberg, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13338 · Cited by 37
Self-citation
Lipoprotein(a): Its relevance to the pediatric population
McNeal, C. J. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.07.006 · Cited by 37
Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria
Lin, J. J., Reilly, M. P., Terembula, K., & Wilson, F. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114397 · Cited by 36
The re-emergence of lipoprotein(a) in a broader clinical arena
Tsimikas, S. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.005 · Cited by 35
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose (NSFA)
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 37
Therapeutic Potential of Lipoprotein(a) Inhibitors
Nicholls, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02046-z · Cited by 39
Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
Chemello, K., Beeské, S., Trang Tran, T. T., Blanchard, V., Villard, E. F., Poirier, B., Le Bail, J.-C., Dargazanli, G., Ho-Van-Guimbal, S., Boulay, D., et al. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.03.008 · Cited by 30
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism
Sticchi, E., Magi, A., Kamstrup, P. R., Marcucci, R., Prisco, D., Martinelli, I., Mannucci, P. M., Abbate, R., & Giusti, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149427 · Cited by 34
The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta‐analysis
Jamialahmadi, T., Reiner, Ž., Alidadi, M., Kroh, M., Almahmeed, W. A., Ruscica, M., Sirtori, C. R., Rizzo, M., Santos, R. D., & Sahebkar, A. (2022) · BioMed Research International · doi:10.1155/2022/8435133 · Cited by 33
Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis
Rudolf, J. W., & Lewandrowski, K. B. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.11.003 · Cited by 34
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
Hardy, J., Niman, S., Goldfaden, R. F., Ashchi, M., Bisharat, M. B., Huston, J., Hartmann, H., & Choksi, R. R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00499-1 · Cited by 35
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 36
Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour
Tavares, V., Pinto, R., Assis, J., Pereira, D., & Medeiros, R. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188331 · Cited by 32
Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin
Buchmann, N., Scholz, M. R., Lill, C. M., Burkhardt, R., Eckardt, R., Norman, K., Loeffler, M., Bertram, L., Thiery, J., Steinhagen‐Thiessen, E., et al. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1036-4 · Cited by 32
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science
Scipione, C. A., Koschinsky, M. L., & Boffa, M. B. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1415866 · Cited by 34
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 31
A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population
Liu, Y., Ma, H., Zhu, Q., Zhang, B., Yan, H., Li, H., Meng, J., Lai, W., Li, L., Yu, D., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.p091009 · Cited by 31
The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors
Blanchard, V., Chemello, K., Hollstein, T., Chong-Hong-Fong, C., Schumann, F., Grenkowitz, T., Nativel, B., Coassin, S., Croyal, M., Kassner, U., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab247 · Cited by 32
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
Koschinsky, M. L., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.017 · Cited by 32
Self-citation
Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention
Yuan, D., Wang, P., Jia, S., Zhang, C., Zhu, P., Jiang, L., Liu, R., Xu, J., Tang, X., Song, Y., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.013 · Cited by 31
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Nekaies, Y., Baudin, B., Kelbousi, S., Sakly, M., & Attia, N. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.08.003 · Cited by 31
Long-term tracking and population characteristics of lipoprotein (a) in the Cardiovascular Risk in Young Finns Study
Raitakari, O. T., Kivelä, A. M., Pahkala, K., Rovio, S., Mykkänen, J., Ahola‐Olli, A., Loo, B.-M., Lyytikäinen, L., Lehtimäki, T. J., Kähönen, M. A. P., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.009 · Cited by 30
Self-citation
Lipoprotein apheresis: an update
Julius, U., Fischer, S., Schatz, U., Hohenstein, B., & Bornstein, S. R. (2013) · Clinical Lipidology · doi:10.2217/clp.13.68 · Cited by 30
Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus
Singh, S. S., Rashid, M., Lieverse, A. G., Kronenberg, F., Lamina, C., Mulder, M. T., de Rijke, Y. B., Sijbrands, E. J. G., & van Hoek, M. (2020) · Diabetologia · doi:10.1007/s00125-020-05120-9 · Cited by 28
Self-citation
Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events
Zanetti, D., Gustafsson, S., Assimes, T. L., & Ingelsson, E. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.002996 · Cited by 31
Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays
Dikaios, I., Althaus, H., Anglés‐Cano, E., Ceglarek, U., Coassin, S., Cobbaert, C. M., Delatour, V., Dieplinger, B., Grimmler, M., Hoofnagle, A. N., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvac203 · Cited by 28
Self-citation
Lack of association of rs3798220 with small apolipoprotein(a) isoforms and high lipoprotein(a) levels in East and Southeast Asians
Khalifa, M. A., Noureen, A., Ertelthalner, K., Bandegi, A. R., Delport, R., Firdaus, W. J. J., Geethanjali, F. S., Luthra, K., Makemaharn, O., Pang, R. W. C., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.015 · Cited by 28
Self-citation
Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen
Karwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N. J., Witztum, J. L., Marcovina, S. M., & Tsimikas, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.036 · Cited by 27
Lipoprotein(a)
Koschinsky, M. L., & Boffa, M. B. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.002 · Cited by 28
Lipoproteins in Atherosclerosis Process
Arnao, V., Tuttolomondo, A., Daidone, M., & Pinto, A. V. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190516103953 · Cited by 27
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 30
Lipoprotein apheresis
Moriarty, P. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000234 · Cited by 27
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 26
Genetics of Dyslipidemia and Ischemic Heart Disease
Sharma, K., & Baliga, R. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0855-9 · Cited by 26
The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Vavuranakis, M., Jones, S. R., Cardoso, R. N., Gerstenblith, G., & Leucker, T. M. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.09.016 · Cited by 26

Authors: Kronenberg, F., & Utermann, G.
Affiliations: Innsbruck Medical University (AT)
Corresponding author: Utermann, G.
ORCID: Kronenberg, F.
Venue: Journal of Internal Medicine
Publisher: Wiley
Published: 2012-11-12
Volume: 273
Issue: 1
Pages: 6-30
ISSN: 0954-6820 (ISSN-L)
1365-2796
DOI: 10.1111/j.1365-2796.2012.02592.x
OpenAlex: W1988877980
Cited by: 521
References: 203
Citations by year: 2026: 40 · 2025: 38 · 2024: 39 · 2023: 41 · 2022: 45 · 2021: 42 · 2020: 36 · 2019: 48 · 2018: 35 · 2017: 36 · 2016: 42 · 2015: 38 · 2014: 20 · 2013: 17 · 2012: 2
FWCI: 4.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Austrian Science Fund
Oesterreichische Nationalbank
Standortagentur Tirol
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords: lipoprotein(a), LPA gene, coronary heart disease risk, genetic risk factors, Mendelian randomization, apheresis, cardiovascular risk reduction
MeSH terms: Alleles, Coronary Artery Disease, DNA, Gene Frequency, Humans, Polymorphism, Genetic, Lipoprotein(a), Genetic Predisposition to Disease, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lipoprotein(a): resurrected by genetics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks